Stock Surge Buzz: Recent chatter on X about Dianthus Therapeutics (DNTH) has been lively following a 6.7% stock price increase on Friday, with shares reaching a high of $37.83. Many users are intrigued by the trading volume, though it was down 51% from the average, sparking curiosity about potential catalysts. This uptick, reported on various financial news platforms, has kept the ticker trending.
Clinical Trial Hype: Discussions also center on the company’s positive Phase 2 trial results for claseprubart in treating myasthenia gravis, with plans for a Phase 3 trial in 2026. Posts on X highlight optimism about the drug’s potential to become a major player in the autoimmune space. The sentiment is fueled by analyst upgrades, with some price targets raised as high as $46.00.
Insider Selling Note: A few X users have pointed out a significant insider sell-off, with over 196,000 shares sold by a key executive, raising eyebrows among investors. While some see this as a red flag, others argue it may not reflect the company’s long-term outlook. This mix of views keeps the conversation dynamic and speculative.
Note: This discussion summary was generated from an AI condensation of post data.
Dianthus Therapeutics Insider Trading Activity
Dianthus Therapeutics insiders have traded $DNTH stock on the open market 5 times in the past 6 months. Of those trades, 0 have been purchases and 5 have been sales.
Here’s a breakdown of recent trading of $DNTH stock by insiders over the last 6 months:
- SIMRAT RANDHAWA (EVP, Head of R&D) has made 0 purchases and 4 sales selling 196,538 shares for an estimated $7,379,887.
- RYAN SAVITZ (CFO & CBO) sold 20,000 shares for an estimated $700,000
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
Dianthus Therapeutics Hedge Fund Activity
We have seen 94 institutional investors add shares of Dianthus Therapeutics stock to their portfolio, and 57 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- WELLINGTON MANAGEMENT GROUP LLP added 2,503,311 shares (+3366.9%) to their portfolio in Q3 2025, for an estimated $98,505,287
- DEEP TRACK CAPITAL, LP removed 2,233,148 shares (-100.0%) from their portfolio in Q3 2025, for an estimated $87,874,373
- VESTAL POINT CAPITAL, LP removed 2,020,000 shares (-63.1%) from their portfolio in Q3 2025, for an estimated $79,487,000
- AVIDITY PARTNERS MANAGEMENT LP added 1,461,282 shares (+83.8%) to their portfolio in Q3 2025, for an estimated $57,501,446
- FMR LLC added 1,426,450 shares (+31.4%) to their portfolio in Q3 2025, for an estimated $56,130,807
- BAIN CAPITAL LIFE SCIENCES INVESTORS, LLC removed 1,166,358 shares (-47.0%) from their portfolio in Q3 2025, for an estimated $45,896,187
- BRAIDWELL LP added 835,057 shares (+inf%) to their portfolio in Q3 2025, for an estimated $32,859,492
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
Dianthus Therapeutics Analyst Ratings
Wall Street analysts have issued reports on $DNTH in the last several months. We have seen 8 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- HC Wainwright & Co. issued a "Buy" rating on 11/10/2025
- Wedbush issued a "Outperform" rating on 11/06/2025
- Truist Securities issued a "Buy" rating on 10/14/2025
- Stifel issued a "Buy" rating on 09/12/2025
- Baird issued a "Outperform" rating on 09/09/2025
- Guggenheim issued a "Buy" rating on 09/09/2025
- Raymond James issued a "Outperform" rating on 09/09/2025
To track analyst ratings and price targets for Dianthus Therapeutics, check out Quiver Quantitative's $DNTH forecast page.
Dianthus Therapeutics Price Targets
Multiple analysts have issued price targets for $DNTH recently. We have seen 8 analysts offer price targets for $DNTH in the last 6 months, with a median target of $64.0.
Here are some recent targets:
- Swayampakula Ramakanth from HC Wainwright & Co. set a target price of $47.0 on 11/10/2025
- Laura Chico from Wedbush set a target price of $46.0 on 11/06/2025
- Danielle Brill from Truist Securities set a target price of $56.0 on 10/14/2025
- Bill Maughan from Clear Street set a target price of $100.0 on 09/17/2025
- Alex Thompson from Stifel set a target price of $65.0 on 09/12/2025
- Steven Seedhouse from Raymond James set a target price of $63.0 on 09/09/2025
- Joel Beatty from Baird set a target price of $67.0 on 09/09/2025
This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.
